VASOCON-A
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOCON-A is a small-molecule ophthalmic solution approved in 1990 for eye-related indications. The mechanism of action and specific indications are not publicly detailed in available records. It is administered as topical eye drops.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100); team focus likely shifting toward transition planning and line extension opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASOCON-A currently shows zero linked job openings, indicating limited hiring on this product line. Working on a LOE-approaching asset requires expertise in defensive strategy, generic competition management, and market transition planning rather than growth acceleration.
Brand ManagerField Sales Representative
Worked on VASOCON-A at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.